These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32832298)

  • 1. Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature.
    Palaiologos K; Ellaboudy A; Abdullah M; Karan S; Saha A
    Cureus; 2020 Jul; 12(7):e9301. PubMed ID: 32832298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
    Abay M; Ozgen L; Yalcin Y; Ozerkan K
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.
    Chong GO; Park JY; Lee HJ
    Am J Case Rep; 2020 Feb; 21():e921146. PubMed ID: 32034117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    Patrono MG; Iniesta MD; Malpica A; Lu KH; Fernandez RO; Salvo G; Ramirez PT
    Gynecol Oncol; 2015 Dec; 139(3):568-72. PubMed ID: 26407480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
    Seidman JD
    Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
    Morrison JC; Blanco LZ; Vang R; Ronnett BM
    Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.
    Ishikawa H; Kiyokawa T; Utsuno E; Matsushita K; Nomura F; Shozu M
    Jpn J Clin Oncol; 2014 Jun; 44(6):597-601. PubMed ID: 24719479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy.
    Yoshida H; Shintani D; Imai Y; Fujiwara K
    Eur J Gynaecol Oncol; 2016; 37(3):404-6. PubMed ID: 27352575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous tubal intraepithelial carcinoma: an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy.
    Vaughan MH; Modesitt SC; Mo Y; Trowbridge ER
    Case Rep Obstet Gynecol; 2015; 2015():760429. PubMed ID: 25802782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
    Shaw PA
    Surg Pathol Clin; 2011 Mar; 4(1):461-78. PubMed ID: 26837301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    Minig L; Cabrera S; Oliver R; Couso A; Rubio MJ; Iacoponi S; Martin-Salamanca MB; Carballo-Rastrilla S; Cádenas-Rebollo JM; García-Garcia A; Gil-Ibáñez B; Juan-Fita MJ; Patrono MG
    Clin Transl Oncol; 2018 Oct; 20(10):1337-1344. PubMed ID: 29623583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I
    Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.